ERBB2 and breast carcinoma: In 2013, the Breast cancer trials of OraL Everolimus-2 (BOLERO-2) data showed the results from final progression-free survival (PFS) analysis of everolimus used in patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer (Yardley et al. 2013).